Global Immuno-Oncology Market is estimated to witness immense growth by 2025

June 26, 2019


Global immuno-oncology market is projected to win commendable gains between 2017-2025, according to the latest research available at Market Study Report LLC, report provides extensively data on market share, growth, trends and forecasts for the period 2017-2025.
 

Immuno-oncology is a biologic treatment that enhances the body's natural defenses against cancer. The therapy uses constituents made by the body or by research laboratory to improve or re-establish the immune system functions.
 

Rapid advancements are being made in immuno-oncology. Several compounds are currently under development and are investigated for use in various forms of cancers. Approved immuno-oncology treatments are also being studied for new uses.
 

Rising occurrence of cancer, technological advancements in immune-oncology, and rising awareness concerning the benefits of ablation procedures is driving the global immuno-oncology market growth. Additionally, advancements in oncology treatments, leading to increased development of pioneering products, are also bolstering market size.
 

Research of novel agents and rise in number of clinical trials, in combinations as well as monotherapy, is further driving industry growth. Notably, the latest agents in immuno-oncology include IDO's, LAG-3, TIM-3, VISTA, NKG2A, B7-H3/H4, TIGIT, KIR. The report also emphasizes the Neo-Antigen therapies, Oncolytic viruses, TCR, and CAR-T therapies.
 

Based on treatment, the global immuno-oncology market is classified into Therapeutic Vaccines, Checkpoint Inhibitors, Monoclonal Antibodies, and Cytokines. In 2017, checkpoint inhibitor was slated to be the largest treatment process segment, accounting for 54.7% of the overall revenue, cites the study.
 

Based on novel targets, the global market is divided into LAG-3 CPI, STING agonist, oncolytic virus, IDO1i, TLR agonist, VEGFi, MEKi, TIGIT, HDACi, TIL, CPI, TGF-b trap, GITR agonist, and A2AR antagonist/CD73i. VEGFi was the largest novel target segment in 2017 with a total market share of 11.2%.
 

Request sample copy of this Reporthttps://www.marketstudyreport.com/request-a-sample/1695103/
 

Based on tumor type, the global immuno-oncology market is segmented into Melanoma, Renal Cell Carcinoma, Head, Face & Neck Cancer, Classical Hodgkin's Lymphoma, Non-Small Cell Lung Cancer, Bladder Cancer, Merkel Cell, and carcinoma. In 2017, classical hodgkin's lymphoma recorded the largest revenue share (15.31%) in the immuno-oncology market.
 

Geographically speaking, North America was one of the largest regional market in 2017. U.S. owns a major market share primarily due to its huge cancer population. The country has recorded numerous innovations in immuno-oncology treatments and processes lately. This is driving the North America market, which is estimated to grow further over the forecast period.
 

Major players operating in global immuno-oncology market include Merck, AstraZeneca, Bristol Myers Squibb, Roche Holding AG, Pfizer Inc., and Incyte Corp. among others. The company profiles of leading players are summarized in the report alongside their business overview, product benchmarking, financials, and recent developments.
 

The report also offers a brief synopsis of global immuno-oncology market with respect to Porter’s five forces, market forces, industry trends, ecosystem analysis, competitive ranking analysis, and PEST analysis.